MAP2K5 and sarcoma: The finding that mice expressing constitutively active MEK5 develop sarcomas, together with the results of in silico studies that pointed to sarcoma as the type of tumor in which ERK5 is most frequently altered, prompted preclinical studies aimed at determining whether modulation of the ERK5 pathway could be therapeutically relevant for that disease.